Company intelligence / Profile preview

RNAConnect

Branford, Connecticut, United Statesrnaconnect.com ↗

Ownership: Private
Development stage: Commercial

Overview

RNAConnect has launched a suite of innovative enzymatic tools—most notably UltraMarathonRT—for accurate end-to-end cDNA synthesis from any RNA template. Their technology enables more complete and unbiased detection of full-length transcripts, isoforms, noncoding RNAs, and complex structures that were previously difficult to analyze with legacy reverse transcriptases. The company’s reagents are designed to power advanced research in genomics and molecular medicine by providing higher fidelity data for applications such as RT-PCR/qPCR and sequencing.

Therapeutic areas: Other
Modalities: Enzyme (Reverse transcriptase)Research reagent/toolBiologic (as the enzyme product)
Industry: Non-Drug Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on RNAConnect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNAConnect.

Explore the full profile